Abstract: Method for the prevention of colonic adenomas in mammals at risk of developing them by administering to such mammals an effective colonic adenoma preventive amount of ursodiol or a pharmaceutically acceptable salt conjugation product thereof.

Abstract: A method for the treatment or prevention of osteoporosis in higher mammals is disclosed, the method comprising administering Insulin-like Growth Factor I (IGF-I) in an effective amount thereof to said mammal, said mammal being in need of said treatment or prevention. Compositions for pharmaceutical use in the above method are also described.

Abstract: When used in admixture with mancozeb, chlorothalonil, a copper salt, folpet, fluazinam or cymoxanil (it being possible for the latter to be used also together with one of the other five components), metalaxyl having a high R-enantiomer content of more than 70% by weight, or pure R-metalaxyl, exhibits a markedly increased fungicidal action against plant diseases as compared with a similar mixture in which metalaxyl is used in the form of the racemate.

Abstract: Compounds of formula ##STR1## wherein n and Z are as defined in claim 1, and, where appropriate, tautomers thereof, in each case in free form or in salt form, can be used as agrochemical active ingredients and can be prepared in a manner known per se.

Abstract: The invention relates to an herbicidal composition comprising N-[2-(3,3,3-trifluoropropyl)-phenylsulfonyl]-N'-(4-methoxy-6-methyl-1,3,5- triazin-2-yl)-urea or an agrochemically tolerated salt thereof, and a synergistic amount of an herbicide which is 3,5-dibromo-4-hydroxybenzonitrile or 3,6-dichloro-2-methoxybenzoic acid.

Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacture of said recombinant antibodies and said monoclonal antibodies, hybridoma cells secreting said monoclonal antibodies, a method of manufacture of said hybridoma cells, DNA coding for the heavy chain variable domain, for the light chain variable domain and for the recombinant antibody, a method of manufacture of said DNA, hybrid vectors suitable for expression of said DNA, host cells transformed with said DNA, and the use of said recombinant antibodies and said monoclonal antibodies in the diagnosis and treatment of tumors.

Abstract: The invention relates to a process for the production of biologically active, dimeric TGF-.beta., to novel TGF-.beta.s and pharmaceutical compositions comprising it. TGF-.beta. produced by this process can be used in various therapeutic modalities.

Abstract: Compounds of the formula I ##STR1## and disulfides thereof and salts thereof are important intermediate products for the preparation of compounds having a microbicidal and plant-immunizing action, of the formula III ##STR2## In the compounds of the formulae I and III: X is halogen,n is 0, 1, 2 or 3;Z is CN, CO-A or CS-A,A is hydrogen, halogen, OR.sub.1, SR.sub.2 and N(R.sub.3)R.sub.4 ;R.sub.1 to R.sub.4 are hydrogen, a substituted or unsubstituted, open-chain, saturated or unsaturated hydrocarbon radical containing not more than 8 carbon atoms, a substituted or unsubstituted cyclic, saturated or unsaturated hydrocarbon radical containing not more than 10 carbon atoms, substituted or unsubstituted benzyl or phenethyl, a substituted or unsubstituted alkanoyl group containing not more than 8 carbon atoms, a substituted or unsubstituted benzoyl group or a substituted or unsubstituted heterocyclyl radical; or R.sub.3 and R.sub.

Abstract: The utility of known and novel staurosporin derivatives of formula I ##STR1## wherein R.sub.1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical,R.sub.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, benzoyl, lower alkanoyl or .alpha.-aminoacyl having a free or protected amino group, andR.sub.3 is hydrogen, hydroxy, lower alkoxy or oxo,or whereinR.sub.1 is methoxycarbonylmethyl,R.sub.2 is benzoyl, andR.sub.3 is hydrogen,for avoiding or removing multi-drug resistance to anti-tumour agents, such as vinblastine or adriamycin, is described.

Abstract: Particularly the invention relates to the compounds of formula I ##STR1## wherein Ar represents carbocyclic aryl, heterocyclic aryl or biaryl;R.sub.1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl, halo-lower alkyl;R.sub.2 represents hydrogen or lower alkyl;R.sub.3 and R.sub.4 represent independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R.sub.3 and R.sub.4 together represent lower allylenedioxy;n represents an integer from 1 to 5;pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof; methods for preparation thereof;pharmaceutical compositions comprising said compounds; and a method of inhibiting TNF-alpha activity and matrix-degrading metalloproteinases in mammals using such compounds.

Abstract: The compounds of formula I are described ##STR1## wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine;R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.7 cycloalkyl;R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.7 cycloalkyl, andR.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl,for use in a method of controlling fleas in domestic animals, especially in dogs and cats, wherein systemic administration is preferred. The compounds of formula I are administered in an amount effective against fleas via the digestive tract or via the blood of the host animal and thus systemically to the domestic animal, especially the dog or the cat.

Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.

Abstract: A topically administrable pharmaceutical composition comprising (A) zinc phthalocyanine, (B) as carrier for (A), (i) a monoalkyl ether of diethyleneglycol substantially in the absence of a N-alkylpyrrolidone, a N,N-dialkylbenzamide or dimethyl sulphoxide, or (ii) a mixture of a monoalkyl ether of diethyleneglycol with a lipid and (C) a gelling agent.

Abstract: A compound of formula ##STR1## where R.sup.1 and R.sup.2 are independently a C.sub.1 -C.sub.10 aliphatic radical, or R.sup.1 is a C.sub.1 -C.sub.10 aliphatic radical and R.sup.2 is a C.sub.6 -C.sub.10 aromatic radical, and R.sup.3 is a C.sub.1 -C.sub.8 aliphatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.6 -C.sub.15 aromatic radical or a C.sub.7 -C.sub.13 araliphatic radical, provided that R.sup.3 is not methyl when R.sup.1 and R.sup.2 are each methyl, that R.sup.3 is not ethyl when R.sup.1 and R.sup.2 are each methyl and that R.sup.2 is not p-aminophenyl when R.sup.1 is methyl and R.sup.3 is ethyl with an organic compound having at least one group reactive with a P--H bond.